+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
H1N1 Vaccines Market - Global Forecast 2026-2032- Product Image
H1N1 Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

H1N1 Vaccines Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904545
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The H1N1 Vaccines Market is projected to reach USD 2.31 Billion in 2026. It is expected to continue growing at a CAGR of 5.13%, reaching USD 3.13 Billion by 2032.

H1N1 vaccines remain a core pillar of global influenza prevention because influenza A(H1N1)pdm09, the virus that emerged during the 2009 pandemic, continues to circulate as a seasonal influenza strain. The World Health Organization estimates seasonal influenza causes 290,000 to 650,000 respiratory deaths each year worldwide, reinforcing the public health value of updated annual vaccination programs.

Demand for H1N1 vaccines is shaped by national immunization recommendations, pandemic preparedness stockpiles, strain-selection decisions, and manufacturing capacity across egg-based, cell-based, and recombinant platforms. For decision-makers, the H1N1 vaccine landscape is not only a seasonal procurement category but also a strategic readiness asset for health security, supply continuity, and high-risk population protection.

Transformative Shifts in the H1N1 Vaccine Landscape

The H1N1 vaccines landscape is shifting from reactive pandemic response toward continuous preparedness, faster strain adaptation, and more resilient production networks. Since the 2009 H1N1 pandemic, which the U.S. Centers for Disease Control and Prevention estimates caused 151,700 to 575,400 respiratory and cardiovascular deaths globally in its first year, governments have strengthened surveillance-linked vaccine planning and emergency procurement frameworks.

Manufacturers are also responding to demand for faster scale-up and diversified production. Egg-based vaccines remain widely used, while cell-culture and recombinant technologies reduce dependence on egg supply chains and can accelerate response timelines. At the same time, broader use of quadrivalent and high-dose influenza vaccines in selected populations has raised expectations for better-matched, risk-targeted immunization strategies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing H1N1 vaccine strategy through faster analysis of viral surveillance data, antigenic drift patterns, adverse-event monitoring, and demand forecasting. AI-supported bioinformatics can help researchers screen candidate antigens and compare viral sequences at scale, complementing the WHO Global Influenza Surveillance and Response System that informs biannual vaccine strain recommendations.

Commercially, AI can improve batch planning, cold-chain allocation, and regional demand prediction during seasonal peaks or outbreak alerts. However, its impact depends on validated datasets, transparent model governance, and regulatory acceptance. For industry leaders, AI is best positioned as an evidence-acceleration layer rather than a substitute for clinical evaluation, strain-selection committees, and pharmacovigilance systems.

Key Regional Insights

Asia-Pacific is a high-priority region due to large populations, dense urban centers, cross-border travel, and strong influenza surveillance investments in countries such as China, Japan, South Korea, India, and Australia. Japan and Australia maintain mature seasonal vaccination infrastructure, while India and China continue to expand domestic vaccine capabilities and public health reach, supporting broader H1N1 vaccine availability during seasonal and preparedness-driven campaigns.

North America benefits from established annual influenza vaccination recommendations, advanced manufacturing capacity, and strong public-private pandemic preparedness mechanisms. Europe is shaped by European Medicines Agency oversight, national immunization schedules, and procurement coordination across EU member states, creating a structured pathway for updated influenza vaccines. Latin America continues to expand seasonal influenza campaigns, with Brazil and Mexico playing important roles in regional procurement and surveillance. The Middle East is influenced by health security planning, international mobility, and mass-gathering preparedness, while Africa faces rising preparedness needs where urbanization, limited cold-chain reach, and variable healthcare access increase the importance of targeted H1N1 vaccine availability.

Key Group Insights

ASEAN countries present strong long-term relevance as governments strengthen immunization systems and prepare for respiratory disease outbreaks in highly connected urban and travel corridors. The GCC is influenced by health security planning, centralized procurement, and seasonal risks linked to mass gatherings and international mobility, making timely H1N1 vaccine access an important component of public health readiness.

The European Union emphasizes regulatory harmonization, pharmacovigilance, and coordinated strain-based approvals, supporting predictable influenza vaccine access across member states. BRICS countries combine large population needs with growing domestic manufacturing capability, particularly in China, India, Brazil, and Russia. G7 nations remain influential in funding influenza research, pandemic preparedness, surveillance modernization, and advanced vaccine technology. NATO countries increasingly view vaccine supply resilience as part of broader biosecurity, civil preparedness, and continuity planning for health systems.

Key Country Insights

The United States remains one of the most influential H1N1 vaccine environments because the CDC recommends annual influenza vaccination for everyone aged six months and older, with emphasis on older adults, pregnant people, young children, and individuals with chronic conditions. Canada follows a similarly structured seasonal influenza approach through national guidance and provincial delivery systems, while Mexico and Brazil rely on public campaigns that prioritize high-risk populations, healthcare workers, and outbreak preparedness.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain national immunization programs supported by strong regulatory oversight, pharmacovigilance, and influenza surveillance systems, while Russia combines domestic production capacity with national vaccination campaigns. China and India are essential to future H1N1 vaccine access due to population scale, expanding manufacturing ecosystems, and evolving adult immunization infrastructure. Japan, Australia, and South Korea represent advanced Asia-Pacific markets with strong surveillance, higher public awareness, established seasonal influenza vaccine channels, and rapid policy responsiveness during respiratory disease threats.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing flexibility, validated strain-update workflows, and supply-chain redundancy across active pharmaceutical ingredients, vials, syringes, adjuvants, and cold-chain logistics. Diversifying across egg-based, cell-based, and recombinant platforms can reduce operational exposure and improve readiness for sudden H1N1 demand spikes.

Organizations should also invest in evidence generation for high-risk groups, real-world effectiveness studies, AI-enabled demand forecasting, and interoperable pharmacovigilance systems. Partnerships with national public health agencies, regional procurement bodies, and surveillance networks will be critical to aligning production decisions with confirmed epidemiological signals rather than speculative demand.

Research Methodology

This executive assessment is grounded in secondary research from recognized public health and regulatory sources, including the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization agencies, and peer-reviewed influenza vaccine literature. The analysis focuses on verified epidemiology, vaccination policy, strain surveillance, technology pathways, and procurement dynamics.

The methodology emphasizes triangulation across public health recommendations, regulatory guidance, disease burden estimates, and technology adoption trends. Market interpretation avoids unsupported forecasts and instead evaluates structural drivers such as seasonal influenza mortality, post-2009 H1N1 surveillance, production platform diversification, regional immunization infrastructure, and pandemic preparedness priorities.

Conclusion

H1N1 vaccines continue to occupy a strategic position within the global influenza prevention ecosystem. Although H1N1 is now part of seasonal influenza circulation, its pandemic history ensures that governments, manufacturers, and healthcare systems treat vaccine readiness as a matter of both routine prevention and emergency response.

The strongest opportunities will emerge for organizations that combine scientific credibility, manufacturing agility, regional access strategies, and data-driven decision-making. As surveillance systems, AI tools, and next-generation vaccine platforms mature, the H1N1 vaccine landscape will increasingly reward preparedness, transparency, and measurable public health impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. H1N1 Vaccines Market, by Type
7.1. Introduction
7.2. Monovalent H1N1 Vaccine
7.3. Trivalent Influenza Vaccine (TIV)
7.4. Quadrivalent Influenza Vaccine (QIV)
7.5. Combination Vaccine
8. H1N1 Vaccines Market, by Antigen Type
8.1. Introduction
8.2. Inactivated
8.3. Live Attenuated
9. H1N1 Vaccines Market, by Manufacturing Platform
9.1. Introduction
9.2. Cell-Culture Based Manufacturing
9.3. Egg Based Manufacturing
9.4. Recombinant Protein Manufacturing
10. H1N1 Vaccines Market, by Dosage Form
10.1. Introduction
10.2. Multi-Dose Vials
10.3. Pre-Filled Syringes
11. H1N1 Vaccines Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Public Health Centers
12. H1N1 Vaccines Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. H1N1 Vaccines Market, by Age Group
13.1. Introduction
13.2. Adults
13.3. Children
14. H1N1 Vaccines Market, by Region
14.1. North America
14.2. Europe
14.3. Asia-Pacific
14.4. Latin America
14.5. Africa
14.6. Middle East
15. H1N1 Vaccines Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. H1N1 Vaccines Market, by Country
16.1. United States
16.2. China
16.3. Canada
16.4. Germany
16.5. Brazil
16.6. Mexico
16.7. Japan
16.8. India
16.9. United Kingdom
16.10. France
16.11. Italy
16.12. Australia
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Laboratories
18.2. Adimmune Corporation
18.3. AstraZeneca PLC
18.4. Bharat Biotech International Limited
18.5. CSL Limited
18.6. Daiichi Sankyo Company, Limited
18.7. GC Biopharma
18.8. GlaxoSmithKline PLC
18.9. Hualan Biological Vaccine Inc.
18.10. Inovio Pharmaceuticals
18.11. Merck & Co., Inc.
18.12. Moderna, Inc.
18.13. Novavax, Inc.
18.14. Panacea Biotec Ltd.
18.15. Pfizer Inc.
18.16. Sanofi S.A.
18.17. Serum Institute of India Pvt. Ltd.
18.18. Sinovac Biotech Ltd.
18.19. Zydus Group
List of Figures
FIGURE 1. GLOBAL H1N1 VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL H1N1 VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL H1N1 VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL H1N1 VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL H1N1 VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL MONOVALENT H1N1 VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL MONOVALENT H1N1 VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL MONOVALENT H1N1 VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL TRIVALENT INFLUENZA VACCINE (TIV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL TRIVALENT INFLUENZA VACCINE (TIV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL TRIVALENT INFLUENZA VACCINE (TIV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL QUADRIVALENT INFLUENZA VACCINE (QIV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL QUADRIVALENT INFLUENZA VACCINE (QIV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL QUADRIVALENT INFLUENZA VACCINE (QIV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL COMBINATION VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL COMBINATION VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL COMBINATION VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CELL-CULTURE BASED MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CELL-CULTURE BASED MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CELL-CULTURE BASED MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL EGG BASED MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL EGG BASED MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL EGG BASED MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT PROTEIN MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT PROTEIN MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RECOMBINANT PROTEIN MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MULTI-DOSE VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MULTI-DOSE VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MULTI-DOSE VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PUBLIC HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 70. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 71. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 72. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 75. NORTH AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 76. EUROPE H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. EUROPE H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 78. EUROPE H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 79. EUROPE H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 80. EUROPE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 81. EUROPE H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 82. EUROPE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 83. EUROPE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 100. AFRICA H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. AFRICA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 102. AFRICA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 103. AFRICA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 104. AFRICA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 105. AFRICA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 106. AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. AFRICA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. NATO H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. NATO H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 119. NATO H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 120. NATO H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 121. NATO H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 122. NATO H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. NATO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. NATO H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 125. G7 H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. G7 H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 127. G7 H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 128. G7 H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 129. G7 H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 130. G7 H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. G7 H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. G7 H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. BRICS H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. BRICS H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 143. BRICS H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 144. BRICS H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 145. BRICS H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 146. BRICS H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. BRICS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. BRICS H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 149. ASEAN H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. ASEAN H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 151. ASEAN H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 152. ASEAN H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 153. ASEAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 154. ASEAN H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. ASEAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. ASEAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 157. GCC H1N1 VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GCC H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 159. GCC H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 160. GCC H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 161. GCC H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 162. GCC H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. GCC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. GCC H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 174. CHINA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. CHINA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 176. CHINA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 177. CHINA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 178. CHINA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 179. CHINA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. CHINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. CHINA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 182. CANADA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. CANADA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 184. CANADA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 185. CANADA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 186. CANADA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 187. CANADA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. CANADA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. CANADA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. GERMANY H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. GERMANY H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 192. GERMANY H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 193. GERMANY H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 194. GERMANY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 195. GERMANY H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. GERMANY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. GERMANY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 198. BRAZIL H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. BRAZIL H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 200. BRAZIL H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 201. BRAZIL H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 202. BRAZIL H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 203. BRAZIL H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. BRAZIL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. BRAZIL H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 206. MEXICO H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. MEXICO H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 208. MEXICO H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 209. MEXICO H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 210. MEXICO H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 211. MEXICO H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. MEXICO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. MEXICO H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. JAPAN H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. JAPAN H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 216. JAPAN H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 217. JAPAN H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 218. JAPAN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 219. JAPAN H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. JAPAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. JAPAN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 222. INDIA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. INDIA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 224. INDIA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 225. INDIA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 226. INDIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 227. INDIA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. INDIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. INDIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. FRANCE H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. FRANCE H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 240. FRANCE H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 241. FRANCE H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 242. FRANCE H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 243. FRANCE H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. FRANCE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. FRANCE H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 246. ITALY H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. ITALY H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 248. ITALY H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 249. ITALY H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 250. ITALY H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 251. ITALY H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. ITALY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. ITALY H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 254. AUSTRALIA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 256. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 257. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 258. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 259. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. SPAIN H1N1 VACCINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. SPAIN H1N1 VACCINES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 280. SPAIN H1N1 VACCINES MARKET SIZE, BY ANTIGEN TYPE, 2017-2032 (USD MILLION)
TABLE 281. SPAIN H1N1 VACCINES MARKET SIZE, BY MANUFACTURING PLATFORM, 2017-2032 (USD MILLION)
TABLE 282. SPAIN H1N1 VACCINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 283. SPAIN H1N1 VACCINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. SPAIN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. SPAIN H1N1 VACCINES MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. GLOBAL H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 287. GLOBAL H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Adimmune Corporation
  • AstraZeneca PLC
  • Bharat Biotech International Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • GC Biopharma
  • GlaxoSmithKline PLC
  • Hualan Biological Vaccine Inc.
  • Inovio Pharmaceuticals
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Zydus Group

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.13 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

H1N1 Vaccines Market Report by Vaccine Type, Market Type, and Region 2026-2034 - Product Image

H1N1 Vaccines Market Report by Vaccine Type, Market Type, and Region 2026-2034

  • Report
  • 150 Pages
  • Global
From
H1N1 Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

H1N1 Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
H1N1 Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

H1N1 Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
H1N1 Vaccine Market Report 2026 - Product Image

H1N1 Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From
H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From

About the H1N1 Vaccine Market

The H1N1 Vaccine is a vaccine developed to protect against the H1N1 strain of influenza, also known as swine flu. It is a type of inactivated vaccine, meaning it contains killed virus particles that are unable to cause infection. The vaccine is administered through injection and is recommended for people of all ages. It is especially important for those at high risk of complications from the virus, such as pregnant women, young children, and people with weakened immune systems. The H1N1 Vaccine market is a subset of the larger Vaccines market, which includes a wide range of products designed to protect against infectious diseases. Vaccines are an important tool in public health, as they can help reduce the spread of disease and protect vulnerable populations. Some companies in the H1N1 Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.